Blue-gray mucocutaneous discoloration: A new adverse effect of ezogabine

JAMA Dermatology

Volumn 150, Issue 9, 2014, Pages 984-989

  Shkolnik, Tali Garin ^a   Feuerman, Hana ^a,b   Didkovsky, Elena ^a   Kaplan, Ilana ^a,b   Bergman, Reuven ^c   Pavlovsky, Lev ^a,b   Hodak, Emmilia ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; MELANIN; OXCARBAZEPINE; RETIGABINE; VALPROIC ACID; ANTICONVULSIVE AGENT; CARBAMIC ACID DERIVATIVE; PHENYLENEDIAMINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ARTICLE; BLUE GRAY SKIN DYSPIGMENTATION; CELL GRANULE; CLINICAL ARTICLE; DRUG EFFECT; DRUG SAFETY; ECHOGRAPHY; ELECTRON MICROSCOPY; FACE DISORDER; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; LIP DISEASE; MASS SPECTROMETRY; NAIL DISEASE; NAIL PIGMENTATION; NUCLEAR MAGNETIC RESONANCE; PALATE DISEASE; PUNCH BIOPSY; RESPIRATORY DISTRESS; SKIN CELL; SKIN DISCOLORATION; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; CASE REPORT; CHEMICALLY INDUCED; DRUG ERUPTIONS; HYPOPIGMENTATION; MUCOSA;

ADULT; ANTICONVULSANTS; CARBAMATES; DRUG ERUPTIONS; FEMALE; HUMANS; HYPOPIGMENTATION; MUCOUS MEMBRANE; PHENYLENEDIAMINES;

EID: 84908234416     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.8895     Document Type: Article

References (15)

1. Stafstrom CE, Grippon S, Kirkpatrick P. Ezogabine (retigabine). Nat Rev Drug Discov. 2011;10(10): 729-730.
2. Amabile CM, Vasudevan A. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy. 2013;33 (2):187-194.
3. Ciliberto MA,Weisenberg JL,Wong M. Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug Healthc Patient Saf. 2012;4:81-86.
4. MingME, Bhawan J, Stefanato CM, McCalmont TH, Cohen LM. Imipramine-induced hyperpigmentation: four cases and a review of the literature. J Am Acad Dermatol. 1999;40(2, pt 1): 159-166.
5. Smith RW, Leppard B, Barnett NL, Millward-Sadler GH, McCrae F, Cawley MI. Chrysiasis revisited: a clinical and pathological study. Br J Dermatol. 1995;133(5):671-678.
6. Massi D, Santucci M. Human generalized argyria: a submicroscopic and X-ray spectroscopic study. Ultrastruct Pathol. 1998;22(1):47-53.
7. Wadhera A, FungM. Systemic argyria associated with ingestion of colloidal silver. Dermatol Online J. 2005;11(1):12.
8. Zachary CB, Slater DN, Holt DW, Storey GC, MacDonald DM. The pathogenesis of amiodarone-induced pigmentation and photosensitivity. Br J Dermatol. 1984;110(4):451-456.
9. Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol. 1992;31(7):458-466.
10. Dereure O. Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253-262.
11. Köstler E, Porst H,Wollina U. Cutaneous manifestations of metabolic diseases: uncommon presentations. Clin Dermatol. 2005;23(5):457-464.
12. Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. Oxford, England:WBSaunders; 2012.
13. Lerner EA, Sober AJ. Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin. Dermatol Clin. 1988;6(2):327-337.
14. US Food and Drug Administration. FDA Drug Safety Communication: anti-seizure drug Potiga (ezogabine) linked to retinal abnormalities and blue skin discoloration. April 26, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm349538.htm. Accessed May 7, 2013.
15. US Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes for anti-seizure drug Potiga (ezogabine) describing risk of retinal abnormalities, potential vision loss, and skin discoloration. October 10, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm372774.htm. Accessed May 14, 2014.